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Abstract We previously cloned a cDNA for a mouse PGE re- 
ceptor positively coupled to adenylate cyclase from mouse masto- 
cytoma cells, and reported it as EP2 subtype of PGE receptor 
]Honda, A., Sugimoto, Y., Namba, T., Watabe, A., Irie, A., 
Negishi, M., Narumiya, S. and Ichikawa, A. (1993) J. Biol. 
Chem. 268, 7759-7762]. However, it is not sensitive to one of the 
EP2 agonists, butaprost. Recently another subtype of PGE re- 
ceptor coupled to adenylate cyelase has been identified pharma- 
cologically and named EP4. These findings have led us to exam- 
ine whether the cloned receptor is the EP4 subtype. AH23848B, 
a selective EP4 antagonist, not only displaced the [3H]PGE2 
binding to the cloned receptor but antagonized the PGE2-stimu- 
lated cAMP formation in the receptor. In contrast, EP2 specific 
agonists, bntaprost and 19(R)OH-PGE 2 neither bound to the 
receptor nor stimulated the cAMP formation. These results sug- 
gest that this receptor previously reported as 'EP2' subtype is 
identical to the pharmacologically defined EP4 subtype and not 
of EP2 subtype. 
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1. Introduction 
Prostaglandin (PG) E2 produces a broad range of biological 
actions in diverse tissues through its binding to specific recep- 
tors on cell membranes [1,2]. PGE receptors were first divided 
into three subtypes, EP1, EP2 and EP3 [3], on the basis of their 
relative sensitivities to various agonists and antagonists. The 
excitatory actions of PGE2 are mediated by EP1 and EP3 recep- 
tors, which are coupled to Ca 2+ mobilization and the inhibition 
of  adenylate cyclase, respectively [3,4]. On the other hand, in- 
hibitory and relaxant activities of PGE2 are believed to be 
mediated by EP2 receptors, coupled to stimulation of adenylate 
cyclase [3]. We previously isolated a cDNA from mouse masto- 
cytoma cells for a mouse PGE receptor and found that it is 
positively coupled to adenylate cyclase [5]. The cloned receptor 
was reported as EP2, because it had properties consistent with 
those reported for the relaxant EP2 receptor [6], except he lack 
of binding of one of the EP2 agonist, butaprost [5]. While we 
isolated and characterized this receptor, Coleman and his col- 
leagues reported a pharmacologically-defined fourth subtype of 
PGE receptor, the EP4 receptor, which, like the EP2 receptor, 
is positively coupled to adenylate cyclase, but which differs in 
the pharmacological ctivity induced by certain ligands, and 
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Abbreviations: PG, prostaglandin; CHO, Chinese hamster ovary. 
they suggested that our cloned receptor may be EP4 subtype 
[7]. It does not respond to butaprost and is sensitive to 
AH23848B [7]. We therefore postulated that the previously- 
cloned 'EP2' receptor may correspond to EP4 reported by 
Coleman. Here we report that our cloned receptor is identical 
to the pharmacologically-defined EP4 receptor. We also de- 
scribe specificity of the receptor for various ligands including 
EP2 agonists. 
2. Materials and methods 
2.1. Materials 
AH23848B, butaprost and I-OH-PGE~ were generous gifts from Dr. 
R.A. Coleman of Glaxo Group Research Ltd, Dr. P.J. Gardiner of 
Bayer UK Ltd. and Dr. D,F. Woodward of Allergan Ltd., respectively. 
[5,6,8,11,12,14,15-3H]PGE2 (179 Ci/mmol) was obtained from DuPont- 
New England Nuclear. PGE2, l l-deoxy PGE, 19(R)OH-PGE 2and 
16,16-dimethyl PGE 2 were purchased from Cayman Chemical (Ann 
Arbor, MI). ~25I-Labeled cAMP assay system was obtained from Amer- 
sham Corp. 
2.2. Stable expression i CHO cells 
cDNA transfection was performed by lipofection [8], essentially as 
described [9]. Chinese hamster ovary (CHO) cells, deficient in dihydro- 
folate reductase (dhfr) activity (CHO-dhfr-) [10], were transfected with 
the cDNA which encodes the cloned receptor [6] inserted into pdKCR- 
dhfr, a eukaryotic expression vector containing a mouse gene of dihy- 
drofolate reductase as a selection marker [1 |]. Selection was performed 
in the c~-modification f Eagle's medium, lacking ribonucleosides and 
deoxyribonucleosides, with 10% dialyzed fetal bovine serum (Cell Cul- 
ture Laboratory). Clonal cell lines were isolated by single-cell cloning 
and screened by RNA blotting. 
2.3. Measurement ofcAMP formation 
The cAMP levels in cells were determined essentially as described 
previously [9]. CHO cells expressing the receptor cultured in 24-well 
plates (5 x 105 cells/well) were incubated for 10 rain at 37°C in HEPES- 
buffered saline (140 mM NaC1, 4.7 mM KC1, 2.2 mM CaCI2, 1.2 mM 
MgCI2, 1.2 mM KH2PO4, 11 mM glucose and 15 mM HEPES, pH 7.4). 
Reactions were started by the addition of the test agents along with 100 
/~M Ro-20-1724. After incubation for 10 min at 37°C, reactions were 
terminated by the addition of 10% trichloroacetic acid. The cAMP 
formed was measured by the radioimmunoassay kit. Apparent pA 2 
value of AH23848B against PGE2 was determined by the method of 
Arunlakshana nd Schild [12]. 
2.4. Membrane preparation and [~H]PGE: binding assay 
[3H]PGE2 binding to the membranes of CHO cells expressing the 
receptor was determined as described previously [13]. CHO cells ex- 
pressing the receptor were harvested, and then homogenized using a 
Potter-Elvehjem homogenizer in an ice-cold solution comprising 10 
mM Tris-HCl (pH 7.4), 1 mM EDTA, 10 mM MgC12, 0.1 mM phen- 
ylmethylsulfonyl fluoride, 20 pM indomethacin and 0.25 M sucrose. 
The homogenate was centrifuged at 800 x g for 5 min, the supernatant 
was further centrifuged at 300,000 × g for 20 rain at 4°C, and the pellet 
was washed once and resuspended in 20 mM HEPES-NaOH (pH 7.4), 
containing 1mM EDTA, 10 mM MgC12 (buffer A), then used for the 
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[3H]PGE2 binding assay. The membrane (40/lg protein) was incubated 
with 4 nM [3H]PGE2 (397,000 dpm) at 30°C for 1 h in 100/ll of buffer 
A, then [3H]PGE2 binding to the membrane was determined as de- 
scribed previously [13]. Non-specific binding was determined using a 
1,000-fold excess of unlabeled PGE 2 in the incubation mixture. The 
specific binding was calculated by subtracting the non-specific binding 
from the total binding. 
3. Resul ts  and d iscuss ion 
We established the CHO cells stably expressing the previ- 
ously reported cloned 'EP2' receptor [6]. The number of the 
expressed receptor is 252 + 6.3 fmol/mg. PGE2 in a concentra- 
tion-dependent manner stimulated cAMP formation in the 
cells, the value of ECs0 being 20 nM (Fig. 1A). This concentra- 
tion-response curve to PGEz was shifted one order toward the 
right in the presence of 30/IM of AH23848B, an EP4 antago- 
nist. Fig. 1B shows the result of the Schild plot analysis ob- 
tained by the AH23848B-induced concentration-dependent 
shift of the response curve to PGE2. A Schild plot regression 
line revealed a linear relationship, and the slope was close to 
unity, indicating that AH23848B behaves as a simple and com- 
petitive antagonist of PGE2 for the receptor. The value of pA2 
is 5.3, and this value is in good agreement with that of 
AH23848B for EP4 receptor eported previously [7]. Further- 
more, AH23848B concentration-dependently i hibited the 
[3H]PGE2 binding to the membrane of the receptor-expressing 
cells, the half-maximal concentration for the inhibition being 
30/~M (Fig. 1C). These results demonstrate hat the cloned 
receptor is the EP4 subtype. 
We next examined the binding affinities of the receptor for 
various PG analogues including EP2 agonists by assessing the 
displacement of [3H]PGE2 binding to the receptor. As shown 
in Fig. 2A, l l-deoxy PGEt, EP2 and EP4 agonist [14], and 
16,16-dimethyl PGE 2, a non-selective EP agonist [15], concen- 
tration-dependently inhibited the [3H]PGE2 binding, their half- 
maximal concentrations for the inhibition being one-order 
higher than that of PGE2. In contrast, butaprost and 19(H)OH- 
PGE2, specific EP2 agonists, showed very weak inhibition, but 
Table 1 
Comparison of binding affinities and cAMP accumulation activities of 
various PGE analogues of the EP4 and EP2 receptors 
EP4 EP2*** 
Ki* ECs0** K,* EC50** 
PGE 2 1.0 1.0 1.0 1.0 
16, 16-Dimethyl PGE2 7.3 2.4 
I 1-Deoxy PGE~ 7.3 0.75 1.9 
1-OH-PGE I 360 17.0 ~r >200 38 
Butaprost >1200 >500 9.5 >34 
19(R)OH-PGE 2 850 >500 30 
*'**The K, values of binding displacement and ECs0 values of cAMP 
accumulation for PGE analogues are shown as equipotent molar atios 
relative to PGE> The K~ and ECs0 values for PGE2 of EP4 and EP2 are 
8.0_+ 0.9 and 53 _+ 14 nM (Ki), and 20 + 3 and 43 + 6 nM (ECs0), 
respectively. Values hown are the means for triplicate determination. 
~Full agonist potency was not observed (partial agonist). ***Regan et 
al. (1994) Mol. Pharmacol. 46, 213-220. 
1-OH-PGE] had stronger inhibition than the EP2 agonists. We 
further examined the agonist activities of several PG analogues 
in the cells. As shown in Fig. 2B, 11-deoxy PGEj concentration- 
dependently stimulated cAMP accumulation with the ECs0 of 
30 nM, which is similar to that of PGE2. 1-OH-PGE~ behaved 
as a partial agonist, but two EP2 agonists, butaprost and 
19(R)OH-PGE2, had no ability to stimulate cAMP accumula- 
tion. Thus, the cloned receptor did not respond to the EP2 
agonists. 
Recently, a human PGE receptor subtype has been cloned, 
which has characteristics of the pharmacologically defined EP2 
subtype [16]. We compared the K~ values of binding displace- 
ment and ECs0 values of cAMP accumulation for PGE ana- 
logues used here between our cloned EP4 receptor and the 
recently reported human EP2 receptor. As shown in Table 1, 
ll-deoxy PGE~ is the good agonist for both EP2 and EP4 
receptors. Butaprost and 19(R)OH-PGE2 are selective EP2 ag- 
onists. The EP4 receptor and EP2 receptor differ in several 
ligand affinity. 
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Fig. 1. Effects of AH23848B on PGE2-induced cAMP formation and PGE2 binding in the cloned PGE receptor-expressing CHO cells. 
(A) Concentration-response curve. After the cells had been preincubated for 30 rain in the absence (©) and presence ( ) of AH23848B (30 raM), 
they were incubated for 10 rain at 37°C with the indicated concentrations of PGE2, and the cAMP formed was determined asdescribed insection 
2. (B) Schild plot for the antagonism by AH23848B against cAMP response to PGE2. The concentration-response curves to PGE 2 were obtained 
after the preincubation with various concentrations of AH23848B. (C) Displacement of [3H]PGE2 binding to the receptor. Unlabeled AH23848B 
(#) or PGE2 (E) was added to the binding assay mixture at indicated concentrations, and specific [3H]PGE2 binding was determined asdescribed 
in section2. The results hown are the means _+ S.E.M. for triplicate determination. 
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Fig. 2. Effects of PGE analogues on [3H]PGE2 binding and cAMP formation. (A) Displacement of [3H]PGE2 binding by various PGs. Unlabeled 
PGs were added to the binding assay mixture at indicated concentrations and specific [3H]PGE2 binding was determined asdescribed insection 2. 
(B) cAMP formation. CHO cells were incubated with the indicated concentrations of PGs along with 100 ~M Ro-20-1724, and the cAMP formed 
was determined as described in section 2. The results hown are the means + S.E.M. for triplicate determination, o, PGE2; e, 1-OH-PGE~; 
A, butaprost; ~, 19(R)OH-PGE2; *, 11-deoxy PGE~; ~, 16,16-dimethyl PGE2. 
We previously revealed that the mRNA for the cloned 'EP2' 
receptor is highly expressed in ileum and thymus, followed by 
lung, spleen, heart and uterus [5]. Whereas pharmacological 
actions of EP4 receptors o far reported are limited to several 
smooth muscles including piglet saphenous vein [7] and rabbit 
ductus arteriosus [17], the study of mRNA expression showed 
that the EP4 receptor is widely distributed in the body and may 
mediate various PGE 2 actions through intracellular cAMP in- 
crease in many tissues and cells. Thymocytes exhibit specific 
PGE binding activity, and PGE 2 inhibits the function and pro- 
liferation ofT cells by increasing cAMP levels [18]. High expres- 
sion of the EP4 receptor in thymus uggest that this inhibitory 
actions of PGE2 are mediated by the EP4 receptor. The EP4 
receptor may play an important role in immune system. We also 
demonstrated that the EP4 receptor is expressed inkidney [19]. 
As based on in situ hybridization study, the EP4 receptor is 
localized to the mesangial cells of glomeruli. In cultured me- 
sangial cells, PGE 2 is known to elicit cAMP formation and 
attenuate he contractility induced by various vasoconstrictors 
[20,21]. This relaxant action of PGE 2 may be mediated by the 
EP4 receptor, and the receptor may be involved in regulation 
of glomerular filtration. The EP4 receptor may regulate a vari- 
ety of cellular functions in the body. 
In summary, we report here that the PGE receptor cloned 
from mastocytoma cells is identical to pharmacologically de- 
fined EP4 receptor. This work clearly demonstrates difference 
in ligand specificity between the EP4 and EP2 receptors and will 
be useful for understanding diverse physiological roles of PGEz 
through PGE receptor subtypes. 
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